Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994061 | 1.00 | ADORA1 (0.77) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL4134920 | 1.00 | ADORA1 (0.77) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL9496017 | 1.00 | ADORA1 (0.77) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL9142291 | 1.00 | ADORA1 (0.77) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL17921080 | 0.90 | ADORA3 (0.72) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL8820476 | 0.90 | LMNA (0.75) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL8820466 | 0.90 | LMNA (0.75) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL5389231 | 0.89 | LMNA (0.71) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL6259651 | 0.89 | LMNA (0.71) | ADORA1ADORA3LMNATP53ADORA2A | |
| SCHEMBL6259647 | 0.89 | LMNA (0.71) | ADORA1ADORA3LMNATP53ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516637-B1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | PLASMIA BIOTECH S L (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-8759034-B2 | Thermostable biocatalyst combination for nucleoside synthesis | PLASMIA BIOTECH, S.L. (ES) | 2014-06-24 | — | — | US | disclosed |
| US-20130337547-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | BRILL ENGINES, S.L. (ES) | 2013-12-19 | — | — | US | disclosed |
| US-8512997-B2 | Thermostable biocatalyst combination for nucleoside synthesis | PLASMIA BIOTECH, S.L. (ES) | 2013-08-20 | — | — | US | disclosed |
| EP-2516637-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | Plasmia Biotech, S.L. (ES) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264175-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | BRILL ENGINES, S.L. (ES) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076894-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338985-A1 | Thermostable biocatalyst combination for nucleoside synthesis | Institut Univ. de Ciència i Tecnologia, s.a. (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-7262176-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262176-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262176-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1414837-B1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040116376-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1414837-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20030078232-A1 | Adenosine receptor A3 agonists | CV THERAPEUTICS, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003014137-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-0253962-B1 | USE OF ADENOSINE DERIVATIVES AS ANTI-DEMENTIA AGENTS | HOECHST JAPAN LIMITED (JP) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078232-A1 | Adenosine receptor A3 agonists | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885ADORA3 1/4885LMNA 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.